Stock AXIM AXIM BIOTECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Market Closed - OTC Markets
Other stock markets
 12:18:53 29/06/2024 am IST 		5-day change 1st Jan Change
0.0099 USD +14.65% Intraday chart for AXIM Biotechnologies, Inc. +32.00% -47.89%
20/05 AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
16/04 AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
AQ
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
AQ
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
AQ
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
BU
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
BU
AXIM Biotechnologies - Optometric Management, Perform a Pre-Fit Ocular Surface Evaluation
AQ
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
AQ
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
AQ
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
AQ
AXIM BIOTECHNOLOGIES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays
AQ
AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing
AQ
AXIM BIOTECHNOLOGIES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
AQ
AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance
AQ
AXIM Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call
AQ
AXIM® Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call
PR
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent
GL
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent
AQ
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions
GL
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AXIM Stock
  4. News AXIM Biotechnologies, Inc.
  5. Press Releases